Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
5 studies found for:    b2355
Show Display Options
Rank Status Study
1 Completed
Has Results
Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Indacaterol;   Drug: Placebo to indacaterol
2 Completed A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006)
Condition: Hepatitis C
Interventions: Drug: Samatasvir tablet;   Drug: Samatasvir capsule
3 Recruiting Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Conditions: Diffuse Large B-cell Lymphoma;   de Novo DLBCL;   DLBCL Transformed From Indolent Lymphoma;   Follicular Grade 3 Lymphoma
Interventions: Drug: Pixantrone + Rituximab;   Drug: Gemcitabine + Rituximab
4 Completed
Has Results
Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects
Condition: Chronic Hepatitis C (HCV)
Intervention: Drug: IDX184
5 Unknown  Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Procedure: Lenalidomide and dexamethasone for four 28-day cycles with or without autologous peripheral blood stem cell transplant.

Indicates status has not been verified in more than two years